Drug intelligence / Profile preview

singletine

Development stage: Phase 1
Lead developer: Cisen Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Singletine is a small molecule drug that acts as a dipeptidyl peptidase IV (DPP-4) inhibitor. It was initially developed by Cisen Pharmaceutical and is being investigated for the treatment of type 2 diabetes mellitus and fatty liver disease. The drug works by inhibiting the DPP-4 enzyme, which increases levels of incretin hormones, thereby enhancing insulin secretion and lowering blood glucose levels. Clinical development has reached Phase 1/2, with studies evaluating its safety, tolerability, pharmacokinetics, and the effect of food on its absorption in healthy subjects[1].

Other names: singletine

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on singletine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on singletine.

Explore the full profile